FutureChem's 40 Billion Won Rights Offering and 20% Stock Dividend Registration Statement Becomes Effective, Confirming 15.1% Dilution and Major Shareholder Stake Drop to 10.08%
The securities registration statement for FutureChem's 40 billion won rights offering and 20% stock dividend became effective on June 30, 2026, finalizing the issuance of 3,389,830 new common shares, resulting in a 15.1% dilution relative to existing shares.
The proceeds will be primarily allocated to R&D: 9.1 billion won for the domestic phase 3 trial of prostate cancer therapy FC705, 4.26 billion won for the US phase 2b trial, and 7.19 billion won for an indication expansion trial.
The combined stake of CEO Ji Dae-yoon and related parties is expected to drop to 10.21% post-offering, and could further decline to 10.08% upon conversion of convertible bonds and exercise of stock options, raising governance stability concerns.
FutureChem reported a 2025 operating loss of 7.75 billion won and a net loss of 11.2 billion won, with negative operating cash flow persisting, requiring close monitoring of financial health.
Outstanding convertible bonds of 3.53 billion won and convertible preferred shares of 1.2 billion won pose additional dilution risk if conversion prices are adjusted downward, potentially pressuring shareholder value.
The company holds 5,227 treasury shares but has no plans for cancellation or additional buybacks, and no separate shareholder return policy has been disclosed.
[AI Summary]The effectiveness of this registration finalizes the capital increase and stock dividend, confirming a 15% dilution that will pressure the stock price in the near term. While the funds will support key pipeline development, ongoing operating losses and the major shareholder's declining stake increase business uncertainty, requiring investors to closely monitor clinical outcomes and future capital needs.